Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Evaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.
How this was made
The 30-second read
Why it matters
The release sets expectations for additional durability and stand-alone activity evidence at ESMO, which can influence investor perception of clinical robustness and potential partnership interest.
Market read
This is a pre-ESMO catalyst announcement for EVX-01 follow-on Phase 2 data, with emphasis on durability and stand-alone use, but no new year-3 numeric outcomes are provided here.
What to watch
Stand-alone (no anti-PD-1) efficacy may be less compelling than combination therapy; investors will likely focus on response durability, relapse rates, and safety in the third-year subset once disclosed.
Background
Evaxion’s EVX-01 is a personalized peptide cancer vaccine studied in advanced melanoma; earlier Phase 2 results (two-year follow-up) were presented last year.
Ticker impact
Evaxion will present three-year Phase 2 efficacy data for EVX-01 in advanced melanoma, including stand-alone (no Keytruda) results.
Moderate upside bias into ESMO as investors price in stronger durability and stand-alone activity; near-term reaction likely limited until data are actually presented.
The article discloses additional follow-on trial-year framing and reiterates strong two-year metrics, but it does not provide new numeric outcomes for year 3 in the text. The main tradable catalyst is the upcoming ESMO presentation window.
Market effects
Supports the personalized cancer vaccine read-through that durable T-cell responses may translate into longer disease control, potentially aiding sentiment for the niche.
Limited; Denmark-based issuer with US listing, event is European (ESMO) but likely global biotech sentiment impact.
Moderate; melanoma immunotherapy and personalized vaccine durability are broadly relevant to oncology investors.
Counterpoint
Without year-3 quantitative results in the release, the market may treat this as promotional until the actual ESMO poster details are published.
Key entities
- companyEvaxion A/S
NASDAQ-listed clinical-stage TechBio company developing personalized cancer vaccines using AI-Immunology.
- assetEVX-01
Personalized peptide-based cancer vaccine candidate evaluated in a Phase 2 trial in advanced melanoma.
- eventESMO Congress 2026
European oncology conference where EVX-01 three-year follow-up data will be presented.
- comparatorKEYTRUDA (pembrolizumab)
Merck’s anti-PD-1 therapy used in combination with EVX-01 for the first two years; third-year subset includes stand-alone EVX-01.
